After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the courts with another, accusing Metsera and Novo Nordisk of anticompetitive ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

Walmart Pharmacies to offer weight-loss drug making obesity treatment more accessible for millions nationwide.

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as next week.

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.